Other · developed by ModeX Therapeutics, An OPKO Health Company
MDX2301 is an agent studied for the prevention of COVID-19, given by intravenous infusion, intramuscular injection, or subcutaneous injection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07445971 | Phase 1 | COVID -19 | Recruiting | OPK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
COVID -19COVID-19 (Prevention)
Updated Oct 25, 2026. Something wrong or missing? Report it on the OPK page.
See OPK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OPK catalysts and pipeline →